Fidelity Wise Origin Bitcoin Fund amends trust agreement to allow in-kind share transactions
Gallagher Duncan, a director at Health Catalyst , Inc. (NASDAQ:HCAT), recently sold 4,500 shares of the company's common stock. The transaction, which took place on December 23, 2024, was executed at an average price of $6.9812 per share, totaling approximately $31,415. According to InvestingPro data, the stock has struggled recently, trading well below its 52-week high of $11.41, though analysts maintain a bullish outlook with a consensus "Buy" rating. Following this sale, Duncan holds 74,438 shares in the company. This transaction was conducted under a pre-arranged trading plan established in accordance with Rule 10b5-1. While Health Catalyst isn't currently profitable, InvestingPro analysis indicates the company is expected to turn profitable this year, with six analysts recently revising their earnings estimates upward. The stock currently appears undervalued based on InvestingPro's Fair Value analysis.
In other recent news, Health Catalyst, a leader in healthcare data and analytics, reported positive financial outcomes for the third quarter of 2024. The company's leadership team, including CEO Dan Burton, CFO Jason Alger, and COO Dan LeSueur, provided insights into the company's performance and future outlook, emphasizing forward-looking growth strategies and financial expectations for the remainder of 2024 and the full year of 2025.
In addition to its earnings report, Health Catalyst's target price has been increased by two financial services firms. Piper Sandler raised the target to $12, up from the previous $11, while maintaining an Overweight rating. The firm's optimism is based on the company's anticipated robust year-over-year growth of approximately 50% in adjusted EBITDA for the calendar year 2025.
Simultaneously, Stephens increased the target price for Health Catalyst to $9, up from the previous $7, while maintaining an Equal Weight rating. This adjustment follows Health Catalyst's third-quarter performance, which included a modest EBITDA beat and an affirmation of its full-year 2024 bookings forecast.
These are the recent developments for Health Catalyst, which continues to navigate the dynamic healthcare landscape. As the company continues to drive growth and deliver value, stakeholders will be closely watching its performance against the projections shared in its earnings call.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.